AmorChem-backed NuChem Therapeutics completes MBO
NuChem Therapeutics Inc, a Montréal-based drug discovery and development contract research organization backed by AmorChem, has completed a management buyout (MBO). NuChem management, consisting of Marc LeBel, Daniel Guay, Marc Janes and John Mancuso, acquired 95 percent of AmorChem's voting shares. Terms weren't released for the deal, which was funded by Investissement Québec and Fonds de Transfert d’Entreprises du Québec. NuChem, a specialist in medicinal and synthetic chemistry services, launched in 2011 with the support of AmorChem, a Canadian early-stage life sciences venture capital firm. It helped develop several of AmorChem's projects with Québec research centres.
22 February 2019•3 mins read
